BioCryst Pharmaceuticals, Inc. · NASDAQ:BCRX
BioCryst Pharmaceuticals — Q1 2021 Earnings Presentation
6 slides from BioCryst Pharmaceuticals's earnings presentation, May 6, 2021
Slide 1: First Quarter 2021 Results Call
First Quarter 2021 Results Call Corporate Update & Financial Results May 6, 2021
Slide 2: Forward-Looking Statements
Forward-Looking Statements BioCryst’s presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertain
Slide 3: Agenda
Agenda ◆ Corporate Update: Jon Stonehouse – President and Chief Executive Officer ◆ Global ORLADEYO™ (berotralstat) Launches: Charlie Gayer – Chief Commercial Officer Megan Sniecinski – Chief Business Officer ◆ BCX9930 Update Dr. Bill Sheridan – Chief Medical Officer ◆ Financial Update Anthony Doyle
Slide 4: Significant Milestones in 2021
Significant Milestones in 2021 Q12021 Q22021 Q32021 Q42021 Approval decision Approval decision on ORLADEYO on ORLADEYO in EU in Japan BCX9930 Advanced Development Trials (January 2021) Revenues reported from Q1/first full quarter of ORLADEYO sales in US Data from completed BCX9930 dose Launch of ORL
Slide 5: Cash position (in millions)
Cash position (in millions) Cash, cash equivalents, restricted cash & investments at December 31, 2020 $303 Cash, cash equivalents, restricted cash & investments at March 31, 2021 $244 Senior credit facility A $125 A – From Athyrium Capital Management, $125M interest-only for 5-year term In the laun
Slide 6: First Quarter 2021 Results Call
First Quarter 2021 Results Call Corporate Update & Financial Results May 6, 2021
BioCryst Pharmaceuticals — Q1 2021 Earnings Presentation on 6ix